AMEH Company Profile

The markets are digesting the 0.983%, increase at the company all along the second quarter of 2022

Sales rise of 0.983 %, could not prevent income decline of -31.25 % in the November to January 31 2023, from similar reporting season a year before. Sales were at $6.98 millions and eps at $0.11.

The company announced Sales of $3.452357 millions, in thefourth quarter of 2022 financial report

Ftac Zeus Acquisition Corp disclosed $3.452357 millions, in Sales in the October to December 31 2022 interval.

Vanishing Losses at the Biotechnology & Pharmaceuticals company amid the financial fourth quarter of 2022

For the financial fourth quarter of 2022 Eiger Biopharmaceuticals Inc managed to cut its losses on fading revenue, where deficit per share were at $-0.46 in contrast to $-0.64 and revenue decreased by -19.762 % to $2.70 millions relative to $3.36 millions in the comparable financial reporting period a year ago.

For the October to December 31 2022 time-frame company had turn a round to profits by posting EPS of $1.89 per share compare to $-0.64 a year before and net profit per share turned positive from $-2.11 per share from the preceding quarter.

Sales remained unaffected to $0.00 millions from $3.36 millions in the corresponding quarter a year before and sequentially Sales Tumbled from $0.00 millions.

Revenues have been $75.283 millions at the Miscellaneous Financial Services company all along the most recent fiscal period

For the most recent fiscal period Federal Home Loan Bank Of Boston reached zero gain of $0.00 per share compare to $0.00 a year prior and from $0.00 per share from the preceding reporting period.

Sales grew strongly by 54.111 % to $75.28 millions from $48.85 millions in the corresponding reporting period a year prior and sequentially Sales deteriorated by -13.874 % from $87.41 millions.